Dishman Carbogen Q1 FY27 Earnings Call — Analysis (NSE: DCAL)
Dishman Carbogen Amcis reported a weak Q1FY27 with revenue down 4% YoY to ₹677.6 Cr and EBITDA dropping 57% YoY due to order deferral, while working to refinance high-cost debt via a CHF 200M promoter ECB loan.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
Q1FY27 Revenue from Operations ₹677.6 Cr ( -4% YoY ) . New guidance — FY27 fy27 consolidated revenue and e… single-digit growth . New story: Synergistic Tech Transfers to India .
Results
Revenue ₹677.6 Cr -4% YoY; EBITDA ₹60.0 Cr -57% YoY (margin 8.85%); Net Loss ₹57.9 Cr impacted by ₹100 Cr order deferral to H2 and ₹11.7 Cr FX loss.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹677.6 Cr | -4% | yoy · Q1FY27 |
| EBITDA | ₹60.0 Cr | -57.3% | yoy · Q1FY27 |
| CDMO Revenue | ₹534.3 Cr | -12.6% | yoy · Q1FY27 |
| CDMO EBITDA Margin | 6.3% | -1160bps | yoy · Q1FY27 |
| Marketable Molecules Revenue | ₹143.2 Cr | +47.9% | yoy · Q1FY27 |
| Marketable Molecules Margin | 18.6% | -1340bps | yoy · Q1FY27 |
| Loss Before Tax | ₹-51.2 Cr | none · Q1FY27 | |
| Net Loss | ₹-57.9 Cr | -327.6% | yoy · Q1FY27 |
| Finance Cost | ₹37.0 Cr | sequential · Q1FY27 · Reduced vs Q4FY26 | |
| ADC Revenue | ₹150 Cr | none · Q1FY27 · Includes linker, payload, and hyper molecule |
Guidance
FY27 consolidated revenue guided for single-digit growth with EBITDA margin similar to last year, while India operations are expected to grow 30-35% with ~10% operating margin.
What management committed to
- The [tech transfer of a legacy project from Switzerland to Bavla site] should be completed within this financial year [FY27]. — FY27
- The [co-investment facility with Japanese client] is expecting operational to be in the course of next year [CY27]. — FY28
- For FY27, [consolidated revenue] we do expect single-digit growth and EBITDA margin should be similar to what we did last year [FY26]. — single-digit growth, FY27
- For the Indian entity, [FY27 revenue] should increase by at least 30-35% compared to previous year with operating margins close to about 10%. — 30-35% growth, 10% margin, FY27
- [Promoter ECB loan infusion] of up to CHF 200 million at 4% all-inclusive interest cost is planned to conclude in the next 60-90 days. — up to CHF 200 million, Q3FY27
- In FY28-29, [consolidated revenue] should achieve more than 10% growth YoY and EBITDA margin should be closer to 25-26%. — >10% revenue growth, 25-26% EBITDA margin, FY29
Key themes
Order deferral, tech transfers, and debt refinancing
How the narrative shifted
- Synergistic Tech Transfers to India: Transferring mature legacy commercial processes from Switzerland to Indian facilities (Bavla/Naroda) to lower manufacturing costs for clients while improving blended group margins.
- Promoter ECB Debt Refinancing: Replacing high-cost Indian borrowings with low-cost (4%) promoter-infused ECB loans of up to CHF 200M to significantly reduce P&L interest burden.
- Operating Leverage and Quarterly Lumpiness: High fixed employee overhead in Switzerland makes quarterly EBITDA volatile when client shipments shift between quarters, but high incremental margin translates top line to EBITDA.
- Biotech Funding and Demand Normalisation: Biotech funding slowdown and post-pandemic destocking impacted early-phase CDMO demand, prompting targeted commercial and SPRINT initiatives to rebuild order momentum.
Operational commentary
- Appointed Angela Ameriks as new Global Chief Commercial Officer and hired new sales leadership in India to strengthen CDMO pipeline conversion.
- MFDS Korea audit successfully completed at Naroda site; Bavla and Naroda sites both hold approvals from major international health authorities.
- Commercial contract signed for legacy product tech transfer from Switzerland to Bavla site (completion targeted in FY27); second major transfer approved with a Swiss MNC, and three others under discussion.
- Supported U.S. launch of a microcyclic peptide in July from the Naroda site; one late Phase III molecule received U.S. FDA commercial approval recently.
- Second co-investment facility with Japanese innovator client is on track to become operational during CY27.
Analyst Q&A
Q. Q2FY27 guidance and quarterly financial run-rate
Difficult to provide QoQ guidance; business is lumpy and best evaluated over a yearly or 2-3 year horizon.
Q. Promoter financing structure, collateral, and timeline for CHF 200M ECB infusion
Borrowing will be backed by promoter personal assets and guarantees, RBI/shareholder approvals are secured, and execution is expected in 60-90 days with no active plan to pledge listed Dishman shares.
Q. Expected revenue contribution from recently commercialized Phase III molecule
Premature to quantify incremental revenue as they await customer 12-24 month demand forecasts post accelerated approval.
Q. Goodwill balance and amortization timeline
Goodwill on consolidation (>₹4,000 Cr) is non-amortizable under accounting standards and tested annually for impairment; standalone goodwill is amortized down to ~₹550 Cr.
Research and educational content only. Not investment advice.